A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Tekijät: Masoodi Mojgan, Gastaldelli Amalia, Hyötyläinen Tuulia, Arretxe Enara, Alonso Cristina, Gaggini Melania, Brosnan Julia, Anstee Quentin M, Millet Oscar, Ortiz Pablo, Mato Jose M, Dufour Jean-Francois, Orešič Matej
Kustantaja: NATURE PORTFOLIO
Julkaisuvuosi: 2021
Journal: Nature Reviews Gastroenterology and Hepatology
Tietokannassa oleva lehden nimi: NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Lehden akronyymi: NAT REV GASTRO HEPAT
Vuosikerta: 18
Aloitussivu: 835
Lopetussivu: 856
Sivujen määrä: 22
ISSN: 1759-5045
eISSN: 1759-5053
DOI: https://doi.org/10.1038/s41575-021-00502-9
Tiivistelmä
Metabolomics and lipidomics approaches are being used to identify biomarkers for nonalcoholic fatty liver disease (NAFLD). This Review discusses the application of metabolomics and lipidomics in clinical studies and in the identification of key metabolic pathway alterations in NAFLD.Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated biomarkers for diagnosis, prognosis and monitoring of disease progression in response to a given treatment. In this Review, we provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with NAFLD and nonalcoholic steatohepatitis (NASH). In addition, we highlight the key metabolic pathways in NAFLD and NASH that have been identified by metabolomics and lipidomics approaches and could potentially be used as biomarkers for non-invasive diagnostic tests. Overall, the studies demonstrated alterations in amino acid metabolism and several aspects of lipid metabolism including circulating fatty acids, triglycerides, phospholipids and bile acids. Although we report several studies that identified potential biomarkers, few have been validated.
Metabolomics and lipidomics approaches are being used to identify biomarkers for nonalcoholic fatty liver disease (NAFLD). This Review discusses the application of metabolomics and lipidomics in clinical studies and in the identification of key metabolic pathway alterations in NAFLD.Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated biomarkers for diagnosis, prognosis and monitoring of disease progression in response to a given treatment. In this Review, we provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with NAFLD and nonalcoholic steatohepatitis (NASH). In addition, we highlight the key metabolic pathways in NAFLD and NASH that have been identified by metabolomics and lipidomics approaches and could potentially be used as biomarkers for non-invasive diagnostic tests. Overall, the studies demonstrated alterations in amino acid metabolism and several aspects of lipid metabolism including circulating fatty acids, triglycerides, phospholipids and bile acids. Although we report several studies that identified potential biomarkers, few have been validated.
Turun yliopiston Tutkimustietojärjestelmän portaali